Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Fineline Cube Dec 29, 2025
Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Fineline Cube Dec 29, 2025
Company Deals

Qure Biotechnology Secures RMB 100 Million Series C1 Financing

Fineline Cube Jun 6, 2025

China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...

Company Drug

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic

Fineline Cube Jun 6, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...

Company Drug

Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy

Fineline Cube Jun 6, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...

Company Deals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Fineline Cube Jun 6, 2025

Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...

Company Drug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Fineline Cube Jun 6, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

Fineline Cube Jun 6, 2025

The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...

Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Fineline Cube Jun 6, 2025

China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...

Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Fineline Cube Jun 6, 2025

China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...

Company Deals

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development

Fineline Cube Jun 6, 2025

China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....

Company Deals

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D

Fineline Cube Jun 6, 2025

China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...

Company Drug

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

Fineline Cube Jun 5, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...

Company Drug

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

Fineline Cube Jun 5, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...

Company Deals

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Fineline Cube Jun 5, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...

Company Deals

Genrix Bio Partners with Cullinan Therapeutics for GR1803 License

Fineline Cube Jun 5, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...

Company Drug

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Fineline Cube Jun 5, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...

Company Drug

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Fineline Cube Jun 5, 2025

China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...

Company Drug

Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval

Fineline Cube Jun 5, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...

Company Drug

Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

Fineline Cube Jun 5, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...

Company Drug

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials

Fineline Cube Jun 5, 2025

Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...

Company Drug

NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination

Fineline Cube Jun 5, 2025

Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...

Posts pagination

1 … 84 85 86 … 601

Recent updates

  • UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio
  • Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug
  • Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
  • J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
  • Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio

Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.